This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Insights - Pfizer is facing significant challenges, including a cautious outlook for 2026 and a substantial patent cliff, which may lead to a decline in stock value [3][9] Group 1: Financial Performance and Outlook - Pfizer's shares have recently fallen after a year of modest growth, with future profits expected to be below analyst forecasts due to ongoing challenges [3] - The company is projected to lose $17-$18 billion in annual revenues by 2028 due to expiring patents on key medications [9] - Expected sales for COVID-19 products in 2026 are projected to decrease to $5 billion, a $1.5 billion drop from 2025 estimates, significantly impacting profit outlook [9] Group 2: Risks and Market Behavior - Historical data shows that Pfizer's stock has experienced significant declines during market downturns, including a 39% drop during the Dot-Com Bubble and a 53% drop during the Global Financial Crisis [5] - The company has faced declines of 24% and 29% during the 2018 correction and the COVID-19 pandemic, respectively, indicating vulnerability to market fluctuations [5] Group 3: Pipeline and Innovation Challenges - Pfizer's pipeline execution faces risks due to setbacks, including the discontinuation of the GLP-1R agonist danuglipron and halting of two Seagen pipeline assets [9] - The company aims to develop eight or more oncology blockbusters by 2030, but current challenges may hinder this goal [9]

PresentationAras AzadianCo-Founder, CEO & Director Well, good morning, everyone. Thank you for joining us for the year-end review and corporate update of Avicanna Inc. It's a pleasure to be hosting you this year. Giving you an update on another very exciting and progressive year. I'll be presenting this morning. My name is Aras Azadian, I'm the CEO and Founder of Avicanna Inc. I'm joined by Dr. Karolina Urban, who is leading our research and medical affairs, essentially scientific affairs here at Avicanna. ...

Johnson & Johnson (NYSE:JNJ) is included among the 12 Best Dogs of the Dow to Invest in. BofA Sees J&J’s Premium Multiple as Justified On December 15, BofA raised its price target on Johnson & Johnson (NYSE:JNJ) to $220 from $204. The firm kept a Neutral rating. The firm says J&J’s premium multiple “looks appropriate for its growth plus asset mix.” It is now valuing the stock based on a new FY27 EPS estimate. Johnson & Johnson (NYSE:JNJ) has already had a big year. Shares are up more than 45% in 2025. H ...

Core Insights - Soligenix, Inc. announced extended results from its Phase 2a trial of SGX302 for mild-to-moderate psoriasis, enrolling an additional four patients with an improved topical gel formulation [1] Group 1: Trial Results - SGX302 gel therapy was well tolerated, with no drug-related adverse events reported among patients [2] - Improvements were observed in multiple assessment metrics, including Investigator Global Assessment (IGA) and Psoriasis Activity and Severity Index (PASI) [2] - One patient achieved "Almost Clear" status on the IGA, with a PASI score improvement exceeding 50% [3] Group 2: Comparison with Previous Formulation - The outcomes from the gel formulation were similar or improved compared to the previous ointment formulation, attributed to comparable release characteristics and enhanced application ease [4] Group 3: Overall Study Findings - The initial exploratory phase confirmed that SGX302 effectively improves psoriasis lesions and is well tolerated, suggesting a potential non-carcinogenic treatment option [5] - Following the announcement, Soligenix's stock price decreased by 21.05%, trading at $1.21 [5]

The White House is set to announce drug pricing deals with pharmaceutical heavyweights Novartis AG and Roche Holding AG as soon as Friday, Bloomberg News reported on Wednesday citing people familiar w... ...

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stock is skyrocketing on Wednesday, with a session volume of 2.73 million compared to the average volume of 389.09 thousand, as per data from Benzinga Pro.Processa Pharmaceuticals on Wednesday provided a clinical update on its ongoing Phase 2 study of NGC-Cap, the combination treatment of PCS6422 and capecitabine, in patients with advanced or metastatic breast cancer.Data from the first 16 of 19 patients enrolled indicate that NGC-Cap significantly increases expo ...

Core Insights - Merck & Co. Inc. announced positive topline results from the Phase 3 KEYNOTE-B15 trial for Keytruda in combination with Padcev for muscle-invasive bladder cancer patients eligible for cisplatin-based chemotherapy [1][2] Group 1: Trial Results - The combination of Keytruda (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) showed statistically significant and clinically meaningful improvements in event-free survival (EFS), overall survival (OS), and pathologic complete response (pCR) rates compared to neoadjuvant chemotherapy and surgery [2] - The trial was conducted in collaboration with Pfizer Inc and Astellas Pharma Inc, and the safety profile of the combination was consistent with known safety profiles of each agent, with no new safety signals identified [3] Group 2: Future Plans - Merck plans to share the trial results with regulatory authorities worldwide for potential regulatory filings and will present the data at an upcoming medical meeting [4] - Three additional Phase 3 studies are currently evaluating Keytruda across all stages of bladder cancer, including non-muscle-invasive, muscle-invasive, and metastatic [4] Group 3: Stock Performance - Following the announcement, Merck's stock showed an upward trend, increasing by 0.37% to $98.63 at the time of publication [5]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

RICHMOND, Va., Dec. 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced results from a randomized, double-blind clinical trial published in JAMA Network Open. The study found that both the 100-mg and 300-mg monthly maintenance doses of SUBLOCADE® (extended- release buprenorphine) rapidly reduced opioid use and improved opioid abstinence and were well tolerated, with no new safety signals in individuals with moderate-to-severe opioid use disorder (OUD). Participants across both dose groups e ...